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 It has been previously shown in a semi-quanitative way that c-Myc 
confers androgen-independent prostate cancer cell growth, and a significant finding from 
this work showed AR regulates c-Myc at a posttranscriptional level. The data presented 
here shows that c-Myc protein expression is required for both normal and prostate cell 
growth, however c-Myc mRNA and protein is expressed and maintained differently 
between these two types of cell lines.  
Using a new method, SmartFlares, we are able to show from a single cell method 
without having to extract RNA that c-Myc mRNA remains constant when treated with 
bicalutamide, while c-Myc protein decreases. We propose that an enhancer 21.7 kb 
upstream of the c-Myc gene becomes activated and loops to the c-Myc promoter in 
prostate cancer.  
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INTRODUCTION 
In the normal prostate, intermediate cells that express the androgen receptor (AR) 
migrate from the basal to the luminal layer and terminally differentiate into AR and 
prostate specific antigen (PSA) positive secretory-luminal cells. AR is a nuclear receptor 
and its main role is to function as a DNA-binding transcription factor. It is also thought to 
play a role in the cell cycle as a DNA licensing factor. Studies have shown that in the 
human prostate a small fraction of proliferating cells in the basal compartment do not 
express AR protein, while the AR positive luminal cells are proliferative quiescent. When 
AR is knocked out selectively in luminal cells, these cells become hyper proliferative and 
do not terminally differentiate.
1
 In prostate cancer, AR no longer serves this repressive 
function, and is thought to promote DNA replication pushing the cell cycle forward 
through a gain of function in c-Myc regulation.
1-6
 The androgen receptor was shown to 
promote ligand-independent progression of prostate cancer by upregulating c-Myc.
2-6
 
However, it is not the AR that is acting on the normal androgen-dependent gene 
expression program, but instead a distinct program resulting in androgen-independent 
growth.
7 
It has been previously shown in a semi-quanitative way that c-Myc confers 
androgen-independent prostate cancer cell growth, and a significant finding from this 
work showed AR regulates c-Myc at a posttranscriptional level.
8
 The data presented here 
shows that c-Myc protein expression is required for both normal and prostate cell growth, 
however c-Myc mRNA and protein is expressed and maintained differently between 
these two types of cell lines.  
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Using an immortalized human prostate epithelial cell line, 957 E/hTert, we show 
that c-Myc expression is necessary for cellular growth. Knockdown β-catenin or TCF-4 
causes growth suppression due to simultaneous loss of c-Myc expression. These cells do 
not express androgen receptor (AR), and when transfected by AR maintain a growth 
suppressive response to R1881 (synthetic androgen) due to loss of c-Myc expression at 
both mRNA and protein levels. AR serves a repressive function in normal prostate cells 
causing them to become growth arrested in the presence of androgen. To overcome this, 
these cells downregulate AR in the presence of R1881 and overcome the growth arrested 
state.  
Unlike this epithelial cell line, we show that prostate cancer cell lines (LNCaP, 
LAPC4, and CWR-22Rv1) respond differently. c-Myc expression is no longer suppressed 
by TCF-4 knockdown or the presence of R1881. Treating these prostate cancer cell lines 
with the anti-androgen, bicalutamide, causes loss of c-Myc expression at the protein level 
and suppresses cell growth. Using a new method, SmartFlares, developed by EMD 
Millipore we are able to show from a single cell method without having to extract RNA 
that c-Myc mRNA remains constant (AR mRNA is upregulated) when treated with 
bicalutamide. AR no longer serves a repressive function in prostate cancer cells, and 
instead promotes the cell cycle. Loss of AR protein leads to a loss of c-Myc protein 
expression. We propose that an enhancer 21.7 kb upstream of the c-Myc gene becomes 






Bicalutamide Treatment Experiments Methods 
Cell Culture 
LAPC4 cells were maintained in culture in a humidified 5% CO2 atmosphere at 37°C in 
complete medium consisting of IMDM supplemented with 10% fetal bovine serum, and 1 
nM R1881. 
LNCaP cells were maintained in culture in a humidified 5% CO2 atmosphere at 37°C in 
complete medium consisting of RPMI supplemented with 10% fetal bovine serum. 
Plating of Cells 
For RT-PCR 
LAPC4 and LNCaP cell lines were plated at a density of one million cells per T75 flask. 
The cells were allowed to sit overnight for attachment.  
For SmartFlares 
LAPC4 and LNCaP cell lines were plated at a density of one million cells per T25 flask. 
The cells were allowed to sit overnight for attachment.  
Bicalutamide Treatment 
Following overnight incubation, the media was exchanged for media supplemented with 
10 µM bicalutamide. Control culture media was replaced with media supplemented with 







Harvesting of cells occurred 96 hours (LNCaP) and 120 hours (LAPC4) post-treatment 
with bicalutamide. Total number of cells were quantified using a Nexcelom 
Bioluminescence Cellometer and trypan blue.  
For SmartFlares 
Harvesting of cells occurred 24 hours post-treatment with bicalutamide.  
Total RNA Extraction  
Total RNA was isolated from 2.5 million cells harvested from each flask using the 
RNeasy Mini Kit (Qiagen) according to the manufacturers' instructions.  
cDNA Synthesis  
Total RNA from each sample (5 µg) was reverse transcribed using the iScript
TM
 cDNA 
synthesis  kit (Bio-Rad) using their blend of random hexamers to anchored oligo-dT 
primers in a 20 µL reaction according to the manufacturer’s protocol. No reverse 
transcriptase controls were prepared from untreated cells’ total RNA and no template 
controls were prepared with water in place of total RNA to indicate potential genomic 
DNA contamination in isolated total RNA and contamination of reagents, respectively.  
RNA Quality Determination 
The concentration and purity of the total RNA was spectrometrically determined using a 
NanoDrop 1000™ (Thermo Scientific). The absorbance ratio A260/A280 was used as an 
indicator of protein contamination and A260/A230 as an indicator of polysaccharide, 
phenol, and/or chaotropic salt contamination. 
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Primers and real-time PCR (qPCR) 
c-Myc gene expression was determined using real-time PCR (qPCR). Oligonucleotide 
primers were designed using IDT DNA software (www.idtdna.com). The c-Myc forward 
primer sequence selected was 5’ - GTA GTG GAA AAC CAG CAG CC – 3’ and the c-
Myc reverse primer sequence selected was 5’- AGA AAT ACG GCT GCA CCG AG – 
3’. GAPDH was used as a housekeeping control gene with a forward primer sequence of 
5’- TCC AAA ATC AAG TGG GGC GA – 3’ and a reverse primer sequence of 5’- AAA 
TGA GCC CCA GCC TTC TC – 3’. The 20 µL reactions contained 1 µL of undiluted 
cDNA or no-RT control, 1 µL (10 µM stock) of each primer, 7 µL nuclease free H2O, 




 Supermix. qPCR run was performed on a CFX 96 
(Bio-Rad) with the following cycle parameters: 95°C for 30 s, 40 cycles of 95°C for 5 s, 
60°C for 5 s and 60°C for 5 s.  
SmartFlare Probes 
The probes received were resuspended dropwise in 50 µL of sterile, nuclease-free water 
according to the manufacturer’s protocol (EMD Millipore). Each probe was vortexed for 
10 seconds. The resuspeneded probes were stored at room temperature. The probes were 
diluted at a ratio of 1 to 20 (water:PBS) prior to use. 50 µL of the diluted, desired probe 
was added to the appropriate T25 flask. The cells were then incubated overnight in a 
humidified 5% CO2 atmosphere at 37°C. Four probes were used: cy5-scramble control, 
cy3-scramble control, cy5-Androgen Receptor (AR), cy3-c-Myc. The cy5 and cy3 
scramble probes was used to measure background fluorescence while the other probes, 




Post 16-hour incubation each T25 flask was harvested. Cells were resuspended in MACS 
buffer. The cells were then filtered into 5 mL polystyrene round-bottom tube with cell-
strainer cap from Corning.  
Flow cytometry was performed using a four color BD FACSCalibur.  
Electrophoretic Mobility Shift Assay (EMSA) 
EMSA was performed using a kit from Promega (Cat # E3050). This involves incubating 
a 
32
P end labeled double stranded oligonucleotide probe (i.e. 
5’gctattgctgttctaattacctcattgtct3’) containing the putative ARE (underlined) from the 3’ c-
Myc enhancer (Ref) with bacterial expressed and purified AR DNA binding domain in 
the gel shift binding buffer. Bound probe was separated from unbound probe by gel 
electrophoresis in 5% polyacrylamide at 120 V for 1.5 hrs. Gels were dried and exposed 
to X-ray film. The specificity of the DNA binding domain for the putative binding site is 
confirmed by competition assays using mutated oligonucleotides with mutations (denoted 
by capital letters) in the putative AR binding site (i.e. mutation 1: 
5’gctattgctgttcCaattacctcattgtct3’ and mutation 2: 5’gctattgctgtCcCaattacctcattgtct3’) vs. 
a non-specific mutation outside of the ARE (i.e. mutation 3 
5’gctattgctgttctaattacctcattgCcC3’). 












957 E/hTert Lenti-AR cells lose expression of AR in the presence of R1881 
Using flow cytometry it can be demonstrated that there are two populations of AR 
expressing 957 E/hTert Lenti-AR cells (Figure 6A) In the untreated cells (top panel), the 
majority of cells expressed high AR (96.4%). Treatment of these cells with R1881 leads 
to a decrease in AR expression with the majority of the cells expressing low AR (96.2%). 
Through Western Blot analysis, R1881 treatment for as little as two days with R1881 
reduces AR protein expression, and after 24 days it becomes undetectable. Removal of 
R1881 treatment does not recover AR expression even after 63 days seen in Figure 6B. 
Growth suppression of high AR expressing occurs in the presence of R1881. In Figure 
6C, it can be seen that cells with low AR in the presence or absence of R1881 show the 
same growth potential as high AR expressing cells. Treatment of high expressing AR 
cells leads to growth suppression. To see if other cell lines behave similarly, in Figure 6D, 
PC3 and DU145 cells were also transfected with AR. Expression of AR and c-Myc was 
tested in the absence and presence of R1881. R1881 stabilizes expression of AR in PC3 
AR and DU145 AR cells, but does not in 957 E/hTert Lenti-AR cells. c-Myc expression 
is also constant in PC3 AR and DU145 cells in the absence and presence of R1881. c-













Cells were plated and allowed to attach overnight before being treating with the 
desired SmartFlare for 16 hours. The cy5 and cy3 scramble probes were used to 
determine background fluorescence in order to distinguish a real signal. The regions 
gated as M1 in Figure 12A and B represent the region in which the background signal 
appears, and the region gated by M2 represents real c-Myc or AR signal respectively 
from the fluorophores released by the SmartFlares. The top two panels of Figure 12A 
represent c-Myc expression in untreated control LNCaP and LAPC4 cells resepectively, 
while the bottom panels represent the bicalutamide treated LNCaP and LAPC4 cells 
resepectively. The c-Myc signal is unchanged when comparing the control cells to the 
bicalutamide treated cells in both cell lines. The median c-Myc peak for the LNCaP 
control cells was 18.27, while the bicalutamide treated cells was 24.36. The median c-
Myc peak for the LAPC4 control cells was 30.23, while the bicalutamide treated cells 
was 29.96. This was the expected result based upon the RT-PCR data. In order to design 
a control to test the ability of the SmartFlares to detect a change in expression, we used 
the Androgen Receptor (AR). The top panels in Figure 12B represent AR expression in 
untreated control LAPC4 and LNCaP cells resepectively, while the bottom panels 
represent the bicalutamide treated LNCaP and LAPC4 cells resepectively. In 2011, 
Brown showed that AR is reactivated in castrate resistant prostate cancer (CRPC) and 
leads to increased AR gene expression.
7
 Cell lines treated with bicalutamide showed 
increased expression of AR. We show that bicalutamide treated cells have an increased 
expression in AR through an increase in median peak in both cell lines. The median AR 
peak for the LNCaP control cells was 922, while the bicalutamide treated cells was 1064.  




In normal tissue, c-Myc expression is necessary for cellular growth. This 
expression is mediated through factors β-catenin or TCF-4. Loss of either of these 
reduces or eliminates expression of c-Myc and causes growth suppression. Using prostate 
cancer cell lines (LNCaP, LAPC4, and CWR-22Rv1) we show that c-Myc expression is 
no longer suppressed by knockdown of β-catenin or TCF-4. However, c-Myc expression 
is still required for these cancerous cell lines to proliferate, and the RNA and/or protein 
expression is increased leading to hyper-proliferation  
Bicalutamide, an anti androgen, suppresses the growth of prostate cancer cell 
lines (LNCaP, LAPC4) through knockdown of c-Myc protein, not c-Myc mRNA. Using 
RT-PCR we were able to show that c-Myc mRNA was not affected using bicalutamide. 
To show that this process occurred on an individual cell level, we used SmartFlares. 
Using this method, we are able to show that c-Myc RNA is unaffected when AR protein 
is knocked down through bicalutamide. AR protein plays an important role in preventing 
the degradation of c-Myc protein.    
Regulation of c-Myc is complex and context specific 
c-Myc regulation, has been shown to be tightly controlled, and can occur at 
several levels - transcriptional, transcript processing, and/or translational/post-
translational. It has been shown that c-Myc can be regulated at both the mRNA and 
protein level. c-Myc mRNA and protein regulation was shown through a histone 
demethylase, JMJD1A.
12
 Qi et al. showed JMJD1A to be essential for prostate cancer cell 
growth and survival by promoting recruitment of the androgen receptor (AR) to the c-
Myc gene. This recruitment increased AR dependent transcription of c-Myc mRNA.  It 
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was also shown to reduce the degradation of c-Myc protein levels by interacting with an 
E3 ubiquitin ligase and competing for the c-Myc binding site.
12
   
SIRT3 and CIP2A are two modes of regulating c-Myc protein expression.
13,14
 Gao 
et al. showed that downregulation of SIRT3 (sirtuin family) has been shown to increase 
c-Myc protein levels by decreasing its phosphorylation. Decreased levels of SIRT3 lead 
to suppression of c-Myc phosphorylation and promoted prostate cancer cell growth in 
vitro and in vivo.
13
 Su et al. focused on CIP2A (cancerous inhibitor of protein 
phosphatase 2A). This oncoprotein was shown to be upregulated in prostate cancer. 
Upregulation of CIP2A was linked to increased protein levels of c-Myc.
14
 This 
interaction could potentially lead to a target for therapeutics to regulate c-Myc protein 
levels.   
It was also shown that c-Myc levels could be altered through upregulation of 
other factors. Loda et al. showed USP2a (Ubiquitin-specific protease 2a) to be 
upregulated in half of all prostate cancers. This protease was shown to downregulate 
microRNAs and lead to increased c-Myc expression.
15
  
There is a wide range of diversity in the factors that regulate c-Myc. It is also 
important to point out that this regulation of c-Myc is a context and cell dependent 
process. Niu et al. shows that in ER-, PR-, AR+ breast cancer, AR expression upregulates 
let-7a mRNA, which decreases c-Myc levels.
16
 The specificity of context adds another 
fold of complexity to the regulation of c-Myc. The evidence presented through these 
studies shows that as normal cells progress to cancer, normal mechanisms for regulation 
change allowing for cell survival and proliferation in prostate cancer.   
	23	
Potential mechanism for c-Myc upregulation in prostate cancer 
Yochum et al. described a model for a chromatin interaction network at the MYC 
gene locus in colorectal cancer. They describe the c-Myc proximal promoter serving as a 
“landing pad” for distal elements (response elements, enhancers, super-enhancers) 
coordinating chromatin structure. This network created has a proposed structure of loops 




Gray et al. proposed a new class of RNAs, enhancer RNAs (eRNAs) that facilitate 
enhancer-promoter interaction and/or activate promoter-driven transcription. Knockdown 
of these RNAs caused decreased expression of genes. The group also showed that eRNAs 
promote chromatin loops, keeping them close to the target promoter and preventing 
nonspecific activation of other genes.
19
 Croce et al. and Rinn et al. showed that some of 
these loops attach to the MYC promoter through long noncoding RNAs (lncRNAs). 
Furthermore, specific lncRNAs are only expressed in cancerous tissue.
18,20
 This finding 
provides evidence of certain regulatory elements becoming active only after the onset of 
cancer through upregulation of these lncRNAs.  
Using the idea of chromatin loops, we believe that there is a 5’ c-Myc enhancer 
located 21.7 kb away from the c-Myc promoter. This promoter is not active in normal 
prostate cells. Activation of this enhancer in cancer can lead to upregulation of c-Myc 
mRNA and increased proliferation, tumorigenicity, and survival. In Figure 13, we show 
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